Company research
Acumen Pharmaceuticals, Inc.
CIK 1576885Updated Sep 27, 2026
SecurityABOS · NASDAQ · equity
ABOS price & chart
Loading TradingView…
NASDAQ:ABOS on TradingView ↗In the news
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 122,833,000Source | 238,992,000Source | 310,125,000Source | 196,587,000Source |
| Property, Plant and Equipment, NetUSD | 103,000Source | 73,000Source | — | 165,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 53,989,000Source | 35,627,000Source | 66,886,000Source | — |
| Assets, CurrentUSD | 122,252,000Source | 178,306,000Source | 246,615,000Source | 180,329,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,387,000Source | 6,749,000Source | 3,093,000Source | 2,724,000Source |
| Operating Lease, Right-of-Use AssetUSD | 140,000Source | 266,000Source | 381,000Source | 105,000Source |
| Other Assets, NoncurrentUSD | 350,000Source | 486,000Source | 221,000Source | 151,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 52,403,000Source | 57,176,000Source | 43,152,000Source | 7,812,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 516,803,000Source | 506,985,000Source | 489,453,000Source | 359,949,000Source |
| Retained Earnings (Accumulated Deficit)USD | -446,462,000Source | -325,127,000Source | -222,798,000Source | -170,427,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 83,000Source | -48,000Source | 312,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 70,430,000Source | 181,816,000Source | 266,973,000Source | 188,775,000Source |
| Liabilities and EquityUSD | 122,833,000Source | 238,992,000Source | 310,125,000Source | 196,587,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 30,007,000Source | 27,607,000Source | 12,971,000Source | 7,812,000Source |
| Operating Lease, Liability, CurrentUSD | 150,000Source | 133,000Source | 110,000Source | 105,000Source |
| Accounts Payable, CurrentUSD | 554,000Source | 5,648,000Source | 1,379,000Source | 1,640,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 150,000Source | 284,000Source | — |
| Other Liabilities, NoncurrentUSD | 0Source | 150,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 10,072,000Source | 6,615,000Source | 6,339,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 116,900,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 163,000Source | 273,000Source | 437,000Source | 30,000Source |
| Long-term DebtUSD | 22,396,000Source | 29,419,000Source | 29,897,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,852,000Source | 9,635,000Source | 6,145,000Source | 3,061,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -5,094,000Source | 4,269,000Source | -261,000Source | 552,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -115,538,000Source | -86,215,000Source | -43,064,000Source | -35,153,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 133,933,000Source | 48,027,000Source | -171,671,000Source | 39,185,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 73,000Source | 41,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -34,000Source | 6,928,000Source | 151,753,000Source | 3,907,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 54,220,000Source | 35,859,000Source | 67,119,000Source | 130,101,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,936,000Source | 2,973,000Source | 169,000Source | 0Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 9,852,000Source | 9,635,000Source | 6,145,000Source | 3,061,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 116,900,000Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 100,000Source | 100,000Source | — | — |
| DepreciationUSD | 58,000Source | 63,000Source | 61,000Source | 32,000Source |
| General and Administrative ExpenseUSD | 18,947,000Source | 20,219,000Source | 18,820,000Source | 12,876,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 4,224,000Source | 4,068,000Source | — | — |
| Investment Income, InterestUSD | 7,447,000Source | 14,317,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 59,000Source | 97,000Source | 11,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -121,335,000Source | -102,329,000Source | -52,371,000Source | -42,856,000Source |
| Nonoperating Income (Expense)USD | 2,497,000Source | 11,688,000Source | 8,767,000Source | 2,381,000Source |
| Operating ExpensesUSD | 123,832,000Source | 114,017,000Source | 61,138,000Source | 45,237,000Source |
| Operating Lease, ExpenseUSD | — | — | 128,000Source | 111,000Source |
| Other Nonoperating Income (Expense)USD | -266,000Source | -151,000Source | -83,000Source | -11,000Source |
| Payments of Financing CostsUSD | — | 0Source | 476,000Source | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 7,938,000Source | 121,904,000Source | 3,792,000Source |
| Proceeds from Stock Options ExercisedUSD | 39,000Source | 0Source | 325,000Source | 115,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -123,832,000Source | -114,017,000Source | -61,138,000Source | -45,237,000Source |
| Other Nonoperating Income (Expense)USD | -266,000Source | -151,000Source | -83,000Source | -11,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -121,335,000Source | -102,329,000Source | -52,371,000Source | -42,856,000Source |
| Earnings Per Share, BasicUSD per share | -2Source | -1.71Source | -1.08Source | -1.06Source |
| Earnings Per Share, DilutedUSD per share | -2Source | -1.71Source | -1.08Source | -1.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 60,561,836Source | 60,013,277Source | 48,609,383Source | 40,601,936Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 60,561,836Source | 60,013,277Source | 48,609,383Source | 40,601,936Source |
| Interest Expense (non-operating)USD | 4,224,000Source | 4,068,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 18,947,000Source | 20,219,000Source | 18,820,000Source | 12,876,000Source |
| Interest ExpenseUSD | — | — | 581,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 2,392,000Source |
| Interest Income, OperatingUSD | — | — | 10,791,000Source | — |
| Investment Income, InterestUSD | 7,447,000Source | 14,317,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 59,000Source | 97,000Source | 11,000Source | — |
| Nonoperating Income (Expense)USD | 2,497,000Source | 11,688,000Source | 8,767,000Source | 2,381,000Source |
| Operating ExpensesUSD | 123,832,000Source | 114,017,000Source | 61,138,000Source | 45,237,000Source |
| Operating Lease, ExpenseUSD | — | — | 128,000Source | 111,000Source |
| Research and Development ExpenseUSD | 104,885,000Source | 93,798,000Source | 42,318,000Source | 32,361,000Source |